FDA
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Inves
-
-
-
-
-
-
-
Verrica partner launches YCANTH molluscum treatment in Japan
-
-
-
-
-
-
-
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
-
-
-
-
-
-
Verrica reports 32.8% quarterly growth in YCANTH applicator units
-
-
-
-
-
-
-
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
-
-
-
-
-
-
-
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
-
322,879 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

